Tarsus has scaled revenue from $40.8M in 2024Q2 to $194.6M in 2026Q3 with gross margins holding near 93%, suggesting the commercial product economics are sound.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | -$14.40-886.3% vs -$1.46 | $195M+3.6% vs $188M |
Q3 2026 Aug 6, 2026 | -$0.43-124.2% vs -$0.19 | $174M+2.5% vs $170M |
Q2 2026 May 6, 2026 | -$0.16+60.2% vs -$0.40 | $162M+8.3% vs $150M |
Q1 2026 Feb 23, 2026 | -$0.20-94.2% vs -$0.10 | $152M+4.9% vs $145M |
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:
Tarsus Pharmaceuticals NASDAQ: TARS reported record third-quarter sales for XDEMVY and raised its full-year revenue outlook, citing increased patient demand, deeper prescribing activity among eye care professionals and a growing contribution from retreatment prescriptions.
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to a loss of $0.3 per share a year ago.
Benchmark TARS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Tarsus Pharmaceuticals, Inc. (TARS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $68.60 | $2.95B | -4.53 | 146.71% | -102.93% | -245.72% | — | |
| $100.61 | $6.55B | 25.50 | 0.5% | 17.28% | 21.72% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $12.37 | $154.54M | -52.77 | 14.52% | -7.12% | -74.71% | — | |
| $4.54 | $187.94M | -3.55 | -3.89% | -43.8% | -20.11% | — | |
| $1.15 | $106.57M | -4.37 | — | — | -21.11% | — |
Tarsus Pharmaceuticals, Inc. (TARS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Tarsus Pharmaceuticals, Inc. (TARS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Aug 6, 2026·SEC
Aug 6, 2026·SEC
Get notified when TARS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tarsus Pharmaceuticals, Inc. (TARS) stock FAQ — growth, dividends, profitability & financials explained
Tarsus Pharmaceuticals, Inc. (TARS) reported $682.2M in revenue over the trailing twelve months. Revenue was $451.4M in fiscal year 2025.
Tarsus Pharmaceuticals, Inc. (TARS) grew revenue by 86.3% over the trailing twelve months, compared with the twelve months before.
No. Tarsus Pharmaceuticals, Inc. (TARS) reported a net loss of $702.2M over the trailing twelve months.
Tarsus Pharmaceuticals, Inc. (TARS) had a return on equity (ROE) of -245.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Tarsus Pharmaceuticals, Inc. (TARS) generated $38.0M in free cash flow over the trailing twelve months.
